Genotyping cell-free DNA in lung cancer patients
Official title: Molecular Analysis of the Surnantant of Echoguidated Bronchoscopic Cytopunctions in Lung Cancer
Run by University Hospital, Toulouse · NCT04624373 · Data updated 2026-11-12
This study is testing a less invasive way to check for specific gene changes in lung cancer patients using a blood sample to help doctors make better treatment decisions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Status | Recruiting |
| Started | April 1, 2021 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | April 3, 2025 |
| Trial ID | NCT04624373 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who are scheduled for an EBUS-TBNA due to suspected stage IV lung cancer or have stage IV NSCLC with specific mutations and resistance to targeted therapies.
✕Probably not a fit
Patients who refuse to participate or are under legal tutelage will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on the genotyping of cell-free DNA obtained from the supernatant of EBUS-TBNA procedures in patients with non-small cell lung cancer (NSCLC). It aims to improve the accuracy of tumor genotyping by utilizing liquid biopsy techniques, which are less invasive than traditional tissue biopsies. The study addresses the challenge of limited tissue availability for multiplex analysis of various targetable mutations and markers, particularly in patients with advanced disease. By analyzing the molecular profile of tumors through minimally invasive methods, the study seeks to enhance treatment decision-making for lung cancer patients.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and timely identification of actionable mutations in lung cancer patients, improving treatment outcomes.
How similar studies have gone: Other studies have shown promise in using liquid biopsy techniques for genotyping in cancer, indicating that this approach is gaining traction in the field.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years-old * Patients planned for an EBUS-TBNA for 1. Suspicion of stage IV lung cancer (PET+ mediastinal node(s)) (Cohort 1) 2. Stage IV NSCLC with an EGFR, BRAF, HER2, MET mutation or ALK, RET or ROS1 rearranged NSCLC and acquired resistance to targeted therapy (Cohort 2) * Performance status 0-3 * Informed consent Exclusion Criteria: * Refusal to participate * Patient under legal tutelage
Where it's running
-
Nicolas Guibert
Toulouse, France Recruiting
Study contacts
- Principal investigator: Nicolas Guibert — University Hospital, Toulouse
- Study coordinator: Nicolas Guibert, MD
- Email: guibert.n@chu-toulouse.fr
- Phone: 567778160
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.